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CONCLUSION: There were considerable differences in
the use of medical services by patients with schizophre-
nia. Of the four cohorts examined, clozapine users had
the fewest hospitalizations at baseline and during the fol-
low-up period, but also the highest costs.
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Following recommended dosage and duration protocols
from the start of a treatment episode is essential to
achieving optimal clinical outcomes through pharmaco-
therapy. For retrospective claims database analysis of an-
tipsychotic medications, early refills and/or dose titration
can complicate comparisons of an individual patient’s
dose and duration pattern to recommended protocols.
OBJECTIVE: The objective was to determine whether an
algorithm adjusting for early refills and dose titrations in
antipsychotic claims resulted in significant changes.
METHODS: Antipsychotic prescriptions dispensed be-
tween October 1995 and December 1997 to 21,536 eligi-
ble subjects were extracted from a large US prescription
claims database. Patients starting a new episode—initia-
tors (n  3244)—received their initial antipsychotic med-
ication between October 1996 and December 1996, but
received no antipsychotic agents in the preceding 365
days. Antipsychotics dispensed within 365 days after the
initial agent were used to calculate mean daily dose and
duration for initiators by medication. Paired t tests as-
sessed differences between patient-level dose and dura-
tion measures calculated with and without the algorithm.
RESULTS: Use of the algorithm significantly reduced du-
ration and significantly raised mean daily doses for initia-
tors taking one of seven antipsychotic medications. For
three agents—olanzapine, risperidone, and thioridazine—
both dose and duration differences were significant at p 	
0.0001. Dosing and duration p-values, respectively, for the
other agents were: chlorpromazine (0.0024, 0.0329), halo-
peridol (0.0017, 0.0002), perphenazine (0.0101, 0.0003),
and trifluoperazine (0.0348, 0.0026).
CONCLUSIONS: Applying the algorithm resulted in sig-
nificant changes to antipsychotic dose and duration val-
ues. Therefore, before comparing patterns developed
from retrospective antipsychotic claims to recommended
guidelines, dose and duration must be adjusted to ac-
count for early refills and/or titration.
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OBJECTIVES: To investigate whether the association be-
tween higher healthcare costs and delays or changes in an-
tipsychotic drug therapy, which was found in previous
1-year period study, continue to accrue over a 2-year
period.
METHODS: For this study 1966 patients with schizo-
phrenia covered by the California Medicaid (Medi-Cal)
program were selected. Multiple logistic regression mod-
els were estimated for the likelihood of delaying therapy
and changing therapy and OLS regressions were used to
estimate the cost effects of these drug use patterns in both
1-year and 2-year models.
RESULTS: Of patients, 21.1% did not use an antipsy-
chotic medication in the first year and 17.6% were un-
treated for 2 years. As before, treated patients used sig-
nificantly less psychiatric hospital services over 2 years
($6906, p  0.0025), but more nursing home services
($7508, p  0.0074) and prescription drugs ($962,
p  0.0001). Nearly 28% of patients treated within 2
years delayed the onset of drug therapy more than 30
days. Having started a delayed course of antipsychotic
therapy during the first year was associated with signifi-
cantly higher first year total costs ($5223, p  0.0270).
However, this impact of delayed therapy measured over
2 years decreased to $2678 (p  0.5158). For patients
with no delay in the start of drug therapy, 48% change
therapy in the first year, which increases to nearly 55%
after 2 years. Patients who change drug therapy exhibit
significantly higher costs: $10,517 after 1 year and
$15,206 over 2 years.
CONCLUSIONS: As in the earlier analysis, antipsychotic
drug use patterns in Medi-Cal suggest that standard med-
ications do not meet the therapeutic needs of patients
with schizophrenia, which results in higher total health-
care costs.
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OBJECTIVE: The purpose of this present study was to
ascertain the economic burden due to the annual direct
costs of psychotropic medications used in the manage-
ment of psychiatric disorders in a developing country
with limited financial resources.
METHODS: The direct costs of the psychopharmacologi-
cal agents evaluated were: 1) antidepressants like tricyclic,
SSRI, and newer antidepressants available; 2) antipsychot-
ics like phenothiazines, butyrophenones, and atypical an-
tipsychotics; 3) benzodiazepines and sedatives. The annual
